Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report issued on Thursday. The brokerage set a “hold” rating on the stock.

Separately, HC Wainwright cut their price objective on Oncternal Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, April 15th.

Oncternal Therapeutics Stock Performance

Oncternal Therapeutics stock opened at $8.29 on Thursday. The stock’s 50 day simple moving average is $8.84 and its two-hundred day simple moving average is $8.22. The stock has a market cap of $22.29 million, a price-to-earnings ratio of -0.61 and a beta of 1.26. Oncternal Therapeutics has a fifty-two week low of $5.57 and a fifty-two week high of $13.14.

Oncternal Therapeutics (NASDAQ:ONCT) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($3.11) earnings per share for the quarter, missing the consensus estimate of ($3.09) by ($0.02). The firm had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.17 million. Oncternal Therapeutics had a negative net margin of 5,029.17% and a negative return on equity of 95.87%. During the same period in the previous year, the firm posted ($4.00) earnings per share. On average, analysts predict that Oncternal Therapeutics will post -10.67 earnings per share for the current year.

Insider Transactions at Oncternal Therapeutics

In related news, Director Robert James Wills bought 3,086 shares of the company’s stock in a transaction on Monday, April 8th. The shares were acquired at an average cost of $8.96 per share, with a total value of $27,650.56. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at approximately $89,600. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have purchased a total of 10,714 shares of company stock valued at $92,736 in the last ninety days. 8.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Oncternal Therapeutics stock. Richmond Brothers Inc. lifted its position in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) by 69.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 494,042 shares of the company’s stock after acquiring an additional 203,010 shares during the period. Oncternal Therapeutics makes up approximately 0.3% of Richmond Brothers Inc.’s portfolio, making the stock its 22nd largest position. Richmond Brothers Inc. owned approximately 0.84% of Oncternal Therapeutics worth $148,000 at the end of the most recent quarter. Institutional investors own 16.05% of the company’s stock.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.